Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China
BackgroundAtopic dermatitis (AD), a common chronic inflammatory skin disorder in children, often shows limited response to conventional therapies with potential adverse effects.MethodsThis real-world study evaluated dupilumab—a monoclonal antibody targeting IL-4/IL-13 signaling—in 59 Chinese pediatr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1644875/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850102408436252672 |
|---|---|
| author | Yue Xu Yue Xu Bowen Li Wenge Wang |
| author_facet | Yue Xu Yue Xu Bowen Li Wenge Wang |
| author_sort | Yue Xu |
| collection | DOAJ |
| description | BackgroundAtopic dermatitis (AD), a common chronic inflammatory skin disorder in children, often shows limited response to conventional therapies with potential adverse effects.MethodsThis real-world study evaluated dupilumab—a monoclonal antibody targeting IL-4/IL-13 signaling—in 59 Chinese pediatric patients (aged 6 months–12 years) with moderate-to-severe AD, stratified by body weight. Over a median 33-week follow-up (up to 96 weeks), we dynamically assessed efficacy metrics including Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale, and Dermatology Life Quality Index, alongside systematic surveillance of treatment-emergent adverse events (TEAEs).ResultsAt Week 16, 68.97% (40/58) achieved EASI-75, accompanied by significant symptom relief (68.17% itch reduction; 77.4% quality-of-life improvement). Efficacy persisted beyond Week 16 (>58.82% sustained EASI-75) without age or sex differences. TEAEs occurred in 25.42% (15/59) of patients, primarily conjunctivitis (10.17%) and paradoxical eczema flares (5.08%). Notably, we report the first pediatric cases of acute rash exacerbation within 72 hours post-initial dose (3 patients, EASI increase: 39.90%–61.13%) and a unique late-onset pustular dermatitis with fever.ConclusionThese findings confirm dupilumab’s sustained effectiveness and manageable safety in Chinese children with AD while highlighting the need for vigilance against early paradoxical flares and rare inflammatory reactions, providing critical real-world evidence for long-term use in this population. |
| format | Article |
| id | doaj-art-8caac70b9a614ff1a312bbc671ee9252 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-8caac70b9a614ff1a312bbc671ee92522025-08-20T02:39:45ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16448751644875Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from ChinaYue Xu0Yue Xu1Bowen Li2Wenge Wang3Graduate School of Hebei North University, Zhangjiakou, Hebei, ChinaPediatric Department, Air Force Medical Center, PLA, Beijing, ChinaGraduate School of Hebei North University, Zhangjiakou, Hebei, ChinaPediatric Department, Air Force Medical Center, PLA, Beijing, ChinaBackgroundAtopic dermatitis (AD), a common chronic inflammatory skin disorder in children, often shows limited response to conventional therapies with potential adverse effects.MethodsThis real-world study evaluated dupilumab—a monoclonal antibody targeting IL-4/IL-13 signaling—in 59 Chinese pediatric patients (aged 6 months–12 years) with moderate-to-severe AD, stratified by body weight. Over a median 33-week follow-up (up to 96 weeks), we dynamically assessed efficacy metrics including Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale, and Dermatology Life Quality Index, alongside systematic surveillance of treatment-emergent adverse events (TEAEs).ResultsAt Week 16, 68.97% (40/58) achieved EASI-75, accompanied by significant symptom relief (68.17% itch reduction; 77.4% quality-of-life improvement). Efficacy persisted beyond Week 16 (>58.82% sustained EASI-75) without age or sex differences. TEAEs occurred in 25.42% (15/59) of patients, primarily conjunctivitis (10.17%) and paradoxical eczema flares (5.08%). Notably, we report the first pediatric cases of acute rash exacerbation within 72 hours post-initial dose (3 patients, EASI increase: 39.90%–61.13%) and a unique late-onset pustular dermatitis with fever.ConclusionThese findings confirm dupilumab’s sustained effectiveness and manageable safety in Chinese children with AD while highlighting the need for vigilance against early paradoxical flares and rare inflammatory reactions, providing critical real-world evidence for long-term use in this population.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1644875/fulldupilumabpediatric atopic dermatitisdupilumab-induced paradoxical flaredupilumab-associated pustular dermatitisreal-world study |
| spellingShingle | Yue Xu Yue Xu Bowen Li Wenge Wang Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China Frontiers in Immunology dupilumab pediatric atopic dermatitis dupilumab-induced paradoxical flare dupilumab-associated pustular dermatitis real-world study |
| title | Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China |
| title_full | Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China |
| title_fullStr | Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China |
| title_full_unstemmed | Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China |
| title_short | Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China |
| title_sort | effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis a real world study from china |
| topic | dupilumab pediatric atopic dermatitis dupilumab-induced paradoxical flare dupilumab-associated pustular dermatitis real-world study |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1644875/full |
| work_keys_str_mv | AT yuexu effectivenessandsafetyofdupilumabinthetreatmentofpediatricatopicdermatitisarealworldstudyfromchina AT yuexu effectivenessandsafetyofdupilumabinthetreatmentofpediatricatopicdermatitisarealworldstudyfromchina AT bowenli effectivenessandsafetyofdupilumabinthetreatmentofpediatricatopicdermatitisarealworldstudyfromchina AT wengewang effectivenessandsafetyofdupilumabinthetreatmentofpediatricatopicdermatitisarealworldstudyfromchina |